1333398-75-6

Upstream product

• 1333400-87-5 [2-bromo-4-(pyridin-4-ylcarbamoyl)-benzyl]-carbamic acid tert-butyl ester 
• 1333400-90-0 2'-(tert-butoxycarbonylamino-methyl)-5'-(pyridin-4-ylcarbamoyl)-biphenyl-3-carboxylic acid 
• 7697-26-9 3-bromo-4-methylbenzoic acid 
• 504-24-5 4-aminopyridine 
• 1333400-84-2 3-bromo-4-(tert-butoxycarbonylamino-methyl)benzoic acid 
• 1333400-86-4 3-bromo-4-(tert-butoxycarbonylamino-methyl)benzoic acid methyl ester 
• 1333400-85-3 diBoc-4-aminomethyl-3-bromo-benzoic acid methyl ester 
• 78946-25-5 3-bromo-4-(bromomethyl)benzoic acid methyl ester 
• 104901-43-1 methyl 3-bromo-4-methylbenzoate 

Relevant academic research and scientific papers

3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors

Clinical development of ROCK inhibitors has so far been limited by systemic or local ROCK-associated side effects. A soft drug approach, which involves predictable metabolic inactivation of an active compound to a nontoxic metabolite, could represent an a

HETEROCYCLIC AMIDES AS ROCK INHIBITORS

The present invention relates to new kinase inhibitors of formula (I), more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases.